In Brief: Genzyme Seprafilm
This article was originally published in The Gray Sheet
Executive Summary
Genzyme Seprafilm: Company submits premarket approval application for bioresorbable membrane designed to reduce postoperative adhesion formation in open abdominal and pelvic procedures. The PMA will undergo expedited review at FDA. Last week, Genzyme reported the results of a study showing that 51% of abdominal surgery patients treated with Seprafilm do not develop adhesions 8-12 weeks following surgery ("The Gray Sheet" Oct. 30, In Brief)...